Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Rheumatoid arthritis (RA) is an immune-mediated rheumatic disease (IMRDs) characterized by chronic erosive arthritis and systemic damage to internal organs, leading to early disability and reduced life expectancy in patients. A particularly important place among the systemic manifestations of RA is...

Full description

Saved in:
Bibliographic Details
Main Authors: E. L. Nasonov, L. P. Ananyeva, S. N. Avdeev
Format: Article
Language:Russian
Published: IMA PRESS LLC 2022-12-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/3242
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849400965054070784
author E. L. Nasonov
L. P. Ananyeva
S. N. Avdeev
author_facet E. L. Nasonov
L. P. Ananyeva
S. N. Avdeev
author_sort E. L. Nasonov
collection DOAJ
description Rheumatoid arthritis (RA) is an immune-mediated rheumatic disease (IMRDs) characterized by chronic erosive arthritis and systemic damage to internal organs, leading to early disability and reduced life expectancy in patients. A particularly important place among the systemic manifestations of RA is occupied by interstitial lung diseases (ILD) – the most severe form of pulmonary pathology in RA, defined as RA-ILD, which is pathogenetically associated with risk factors (smoking, etc.) and autoimmune mechanisms underlying RA. RA-ILD is a subtype of RA characterized by a severe course and a poor prognosis. The review presents new data regarding risk factors and biomarkers for RA-ILD; modern diagnostic capabilities based on the use of functional lung tests, high-resolution computed tomography, ultrasound examination of the lungs. Particular attention is paid to the efficacy and safety of pharmacotherapy, including methotrexate, biologics, JAK inhibitors, and antifibrotic therapy. An algorithm for the pharmacotherapy of RA-ILD has been proposed.
format Article
id doaj-art-6aa1a7c164a64ee2bba6cff45fa2e18c
institution Kabale University
issn 1995-4484
1995-4492
language Russian
publishDate 2022-12-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-6aa1a7c164a64ee2bba6cff45fa2e18c2025-08-20T03:37:53ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-12-0160651753410.47360/1995-4484-2022-12855Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonologyE. L. Nasonov0L. P. Ananyeva1S. N. Avdeev2V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)V.A. Nasonova Research Institute of RheumatologyI.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Rheumatoid arthritis (RA) is an immune-mediated rheumatic disease (IMRDs) characterized by chronic erosive arthritis and systemic damage to internal organs, leading to early disability and reduced life expectancy in patients. A particularly important place among the systemic manifestations of RA is occupied by interstitial lung diseases (ILD) – the most severe form of pulmonary pathology in RA, defined as RA-ILD, which is pathogenetically associated with risk factors (smoking, etc.) and autoimmune mechanisms underlying RA. RA-ILD is a subtype of RA characterized by a severe course and a poor prognosis. The review presents new data regarding risk factors and biomarkers for RA-ILD; modern diagnostic capabilities based on the use of functional lung tests, high-resolution computed tomography, ultrasound examination of the lungs. Particular attention is paid to the efficacy and safety of pharmacotherapy, including methotrexate, biologics, JAK inhibitors, and antifibrotic therapy. An algorithm for the pharmacotherapy of RA-ILD has been proposed.https://rsp.mediar-press.net/rsp/article/view/3242rheumatoid arthritisinterstitial lung diseasemethotrexatebiologicsjak inhibitorsantifibrotic drugsnintedanib
spellingShingle E. L. Nasonov
L. P. Ananyeva
S. N. Avdeev
Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
Научно-практическая ревматология
rheumatoid arthritis
interstitial lung disease
methotrexate
biologics
jak inhibitors
antifibrotic drugs
nintedanib
title Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
title_full Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
title_fullStr Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
title_full_unstemmed Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
title_short Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
title_sort interstitial lung disease in rheumatoid arthritis a multidisciplinary problem in rheumatology and pulmonology
topic rheumatoid arthritis
interstitial lung disease
methotrexate
biologics
jak inhibitors
antifibrotic drugs
nintedanib
url https://rsp.mediar-press.net/rsp/article/view/3242
work_keys_str_mv AT elnasonov interstitiallungdiseaseinrheumatoidarthritisamultidisciplinaryprobleminrheumatologyandpulmonology
AT lpananyeva interstitiallungdiseaseinrheumatoidarthritisamultidisciplinaryprobleminrheumatologyandpulmonology
AT snavdeev interstitiallungdiseaseinrheumatoidarthritisamultidisciplinaryprobleminrheumatologyandpulmonology